Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc. (MD) Market Cap

Pediatrix Medical Group, Inc. has a market capitalization of $1.92B.

Financials based on reported quarter end 2025-12-31

Price: $23.12

β–² 0.27 (1.18%)

Market Cap: 1.92B

NYSE Β· time unavailable

CEO: Mark S. Ordan

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1995-09-20

Website: https://www.mednax.com

Pediatrix Medical Group, Inc. (MD) - Company Information

Market Cap: 1.92B Β· Sector: Healthcare

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of February 17, 2022, it operated a network of approximately 2,700 physicians. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.

Analyst Sentiment

62%
Buy

Based on 33 ratings

Analyst 1Y Forecast: $21.86

Average target (based on 3 sources)

Consensus Price Target

Low

$19

Median

$22

High

$27

Average

$22

Downside: -3.8%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ PEDIATRIX MEDICAL GROUP INC (MD) β€” Investment Overview

🧩 Business Model Overview

Pediatrix Medical Group, Inc. (MD) operates as a physician-centric healthcare delivery company with a primary focus on providing specialized services for newborn, maternal-fetal, and pediatric care. Through a network of affiliated clinicians and practices across the United States, the company delivers neonatal, perinatal, pediatric cardiology, pediatric intensive care, and other subspecialist services primarily in hospital and outpatient settings. The business model is founded on long-term service agreements with hospitals and health systems, where Pediatrix supplies clinical staff, manages administrative functions, and orchestrates high-quality care delivery. The company leverages its depth in specialized pediatrics to enhance patient outcomes, adhere to clinical best practices, and provide scalable solutions for partner institutions. Pediatrix also pursues strategic acquisitions and partnerships to expand its service footprint and clinical scope.

πŸ’° Revenue Streams & Monetisation Model

Pediatrix monetizes its clinical services predominantly through a fee-for-service reimbursement model, complemented by contracts with hospitals and health plans. Revenue sources include: - **Professional Fees:** The principal revenue channel arises from third-party payers (both government and commercial insurers) and patient out-of-pocket payments for services rendered by its clinicians. - **Hospital Contracts:** Some arrangements involve hospitals paying Pediatrix a fixed fee or subsidy to ensure consistent 24/7 coverage for critical neonatal or pediatric specialties. - **Management Services:** Ancillary revenue is derived from practice management, consulting, and administrative support for affiliated and partner practices. - **Value-based Care Initiatives:** Pediatrix participates in outcome-driven programs that incentivize clinical efficiency, quality improvement, and cost reductions, which can generate shared savings or performance-based bonuses.

🧠 Competitive Advantages & Market Positioning

Pediatrix’s competitive strength is anchored in its scale, reputation, and clinical focus: - **National Network and Scale:** With one of the largest networks of neonatal and pediatric specialists in the U.S., Pediatrix commands a broad geographic reach and the capacity to staff high-need hospitals efficiently. - **Clinical Leadership and Expertise:** The company is recognized for setting standards and advancing best practices in neonatal and perinatal medicine, which solidifies long-standing relationships with hospital partners and attracts top-tier clinicians. - **Data and Outcomes Capabilities:** Pediatrix leverages advanced clinical informatics and proprietary databases, aiding in continuous outcome improvement and robust population health management. - **Brand Equity:** Longstanding reputation as a premier provider positions the company favorably in contract negotiations and partnership opportunities.

πŸš€ Multi-Year Growth Drivers

Several structural and operational themes underpin Pediatrix’s multi-year growth prospects: - **Demographic Tailwinds:** Steady birth rates and demand for specialized neonatal and maternal care anchor long-term clinical need for core services. - **Hospital Outsourcing Trends:** More health systems are outsourcing specialist staffing to optimize costs, reduce liability, and ensure 24/7 coverage, which aligns closely with Pediatrix’s solution model. - **Service Line Expansion:** The company continues to broaden its portfolio through acquisitions and the build-out of new pediatric subspecialties, creating cross-selling and market penetration opportunities. - **Value-based Care Initiatives:** Transitioning to quality-based reimbursement cultivates additional revenue streams and opens the door for payer partnerships focused on outcomes. - **Operational Leverage and Technology Integration:** Adoption of telemedicine, remote monitoring, and data analytics drive efficiencies and expand the reach of clinicians.

⚠ Risk Factors to Monitor

Investors should be cognizant of several inherent risks: - **Payer Mix and Reimbursement Pressure:** Shifting payment regimes, policy reforms, and tightening reimbursement from governmental and commercial payers can compress margins. - **Regulatory and Legal Risks:** The company faces evolving healthcare regulations and potential litigation risk, especially in a highly regulated pediatric environment. - **Dependency on Hospital Relationships:** Contract concentration with large health systems makes Pediatrix vulnerable to renegotiation cycles, non-renewals, or competitive displacement. - **Labor and Physician Shortages:** The supply-demand imbalance among trained neo- and perinatal specialists poses staffing challenges and may pressure compensation costs. - **Acquisition Integration:** Pursued growth via M&A carries execution risk, including cultural alignment, systems integration, and clinical quality assurance.

πŸ“Š Valuation & Market View

The valuation of Pediatrix Medical Group reflects its defensive positioning within acute care specialties, recurring fee-for-service revenues, and steady cash generation. The company often trades at a multiple consistent with mature healthcare service peers balancing growth, stability, and acquisition-driven upside. Adjusted for risk factors, the market typically ascribes a discount for regulatory uncertainties and reimbursement volatility but recognizes the premium for scale, clinical quality, and long-duration hospital contracts. Enterprise value is also influenced by the stability of free cash flow, capacity for disciplined M&A, and progress on transitioning to value-based models. Investors often benchmark Pediatrix against other specialized healthcare staffing firms and specialty practice aggregators, highlighting relative growth, margin profiles, and capital deployment strategies.

πŸ” Investment Takeaway

Pediatrix Medical Group, Inc. presents a compelling vehicle for investors seeking exposure to specialized healthcare delivery. Its entrenched market position in neonatal and pediatric subspecialties, national platform, and ability to adjust to shifting industry dynamics support a stable, defensive profile over the long term. Growth is underwritten by enduring demographic needs, hospital outsourcing trends, and expansion into adjacent services. That said, vigilant monitoring of payer policy, regulatory landscapes, and execution of growth initiatives remains essential, as these variables could materially impact long-term performance. For investors comfortable with healthcare sector dynamics and associated policy risks, Pediatrix offers a blend of steady cash flows and moderate growth potential, anchored by meaningful clinical relevance.

⚠ AI-generated β€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"MD reported revenue of $493.8M and net income of $33.7M for the latest fiscal year. The company has shown strong growth, particularly reflected in a 42.71% increase in share price over the past year. With a robust operating cash flow of $114.1M and healthy free cash flow at $108.8M, MD exhibits good cash generation capabilities. Its total assets amount to $2.25B, and the company maintains a solid balance sheet with total equity of $865.9M and net debt of $285.1M. However, the absence of dividend payouts may signify a focus on reinvestment rather than direct shareholder returns. MD's price target consensus stands at $20.67, indicating moderate expectations from analysts, aligned with the current market price of $20.75. Overall, MD displays promising growth and operational efficiency, though caution is warranted regarding its valuation and lack of dividends."

Revenue Growth

Good

Strong revenue growth reflecting market capture.

Profitability

Positive

Positive net income with earnings of $33.7M.

Cash Flow Quality

Strong

Strong operating cash flow and free cash flow margins.

Leverage & Balance Sheet

Positive

Healthy balance sheet with manageable debt.

Shareholder Returns

Neutral

High price appreciation, but no dividends.

Analyst Sentiment & Valuation

Positive

Positive analyst outlook but moderate valuation concerns.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management reported strong Q4 and full-year results (Q4 adjusted EBITDA $66M; full-year 2025 adjusted EBITDA $276M) and guided 2026 adjusted EBITDA to $280M–$300M (midpoint ~5% above 2025). However, the Q&A pressure points were not about demand but about policy uncertainty and how much is embedded in guidance: they explicitly assume no measurable change yet in exchange/ACA subsidy effects, while acknowledging that if ACA subsidies lapse without effective remedy, there could be an impactβ€”though they can’t quantify it. On the quarter’s volume softness (patient service volumes down just under 3%; NICU days down ~2%), management attributed it largely to a tough comp. Expense guidance also leans on modest reduction (G&A $230M–$240M vs $241M in 2025), but with no quantified structural savings and no M&A contribution assumed in 2026. Net: confident on near-term base, cautious on policy-driven payer mix.

AI IconGrowth Catalysts

  • Same-unit pricing up just under 7% in Q4 2025 (driven by solid RCM cash collections, favorable payer mix, increased neonatology acuity, and higher contract administrative fees)
  • Same-unit growth of 4% in Q4 2025 supported by stabilization efforts tied to revenue cycle management transition in 2025

Business Development

  • Pediatrix Partners: 46 physicians across specialties receiving stock price tracking grants tied to quality, hospital relations, recruiting/retention, and growth guidance
  • Stock price tracking element for physician cash bonuses: 500+ physicians participating in first-year program

AI IconFinancial Highlights

  • Adjusted EBITDA (Q4 2025): $66,000,000, in line with upwardly adjusted guidance
  • Full-year 2025 adjusted EBITDA: $276,000,000 (described as strong; driven by volume, acuity, payer mix, and strong financial control)
  • 2026 adjusted EBITDA guidance: $280,000,000 to $300,000,000; midpoint is ~5% above 2025
  • 2026 revenue guidance: approximately $1,900,000,000 (management characterizes as in line with 2025; assumes flat volume and flat pricing overall)
  • Q4 2025 revenue: consolidated revenue decreased due to net non-same unit activity of $26,000,000 (including decrease from portfolio restructuring), partially offset by acquisition and organic growth
  • Q4 2025 same-unit trends: same unit growth 4%; pricing just under 7%; patient service volumes down just under 3%; NICU days down about 2%
  • G&A (2026): expected $230,000,000 to $240,000,000 vs 2025 $241,000,000; achieving mid-range implies ~20 bps decline as % of revenue
  • Cash flow (Q4 2025): operating cash flow $115,000,000 vs $135,000,000 prior year (linked to decreases in cash flow from AP and accrued/other liabilities)
  • Balance sheet (Q4 2025): cash $375,000,000; net debt just over $220,000,000; net leverage just under 1x; AR DSO 42.8 days (down ~5 days YoY)
  • Guidance risk framing: 2026 outlook assumes steady metrics from 2025; does not assume M&A contribution in 2026

AI IconCapital Funding

  • Share repurchase (Q4 2025): $64,000,000 deployed to buy 2,900,000 shares; ended with just about 83,000,000 shares outstanding
  • Management indicated 2026 guidance assumes only a small, smaller-scale stock buyback vs 2025 (amount not quantified beyond 'small/much smaller')
  • Ending cash $375,000,000 with net leverage <1x; described as providing investment flexibility

AI IconStrategy & Ops

  • Physician alignment/compensation redesign: portion of physician bonuses shifted to stock price tracking elements paid over multiple years
  • Revenue cycle management: Q4 pricing strength attributed to stabilization efforts from 2025 RCM transition (RCM cash collections cited as a key driver)
  • Growth footprint strategy: leverage telemedicine where physical footprint limits access; seek additional physical growth in NICUs and maternal fetal medicine and via OB hospital medicine (OBH)
  • OBH expansion approach: using existing hospital relations (NICU/PICU/MFN) as an entree and claiming potential cost advantage to hospital partners

AI IconMarket Outlook

  • 2026 revenue expected ~flat with 2025 (~$1.9B), with management stating overall volume and pricing assumed flat (ups/downs within components)
  • First-quarter 2026 seasonality: Q1 adjusted EBITDA expected to be ~17% to 19% of full-year annual expected range (historical range 17% to 21%)
  • Volume comps: management cited tough prior-year fourth quarter comp as primary reason for Q4 volume decline

AI IconRisks & Headwinds

  • ACA exchange/subsidy risk: management said guidance assumes payer mix benefit in 2025 from ACA subsidies; if those subsidies lapse without remedy, they expect an effect but noted it is 'very difficult to quantify' due to multiple possible outcomes
  • Exchange/enrollment policy uncertainty (analyst Q&A): government enrollment change details and any 'stop gap' not yet defined; enrollment/payment outcomes by individuals uncertain; management therefore assumes 'same metrics as 2025' in guidance
  • Volume headwind in Q4 2025: patient volume down just under 3% and NICU days down about 2% attributed to tough comp rather than identified single operational failure
  • Cost/expense dynamics: variable incentive compensation and salary/benefits increased on same-unit basis in Q4 (no precise bps figure given), while salary growth modestly below prior six-quarter average (~3%)

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the MD Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (MD)

Β© 2026 Stock Market Info β€” Pediatrix Medical Group, Inc. (MD) Financial Profile